.png)
Anti-allergy Nasal Spray
.png)
Anti-allergy Nasal Spray
ClorNasal is a powerful intranasal anti-allergy and rhinitis treatment developed by Dr. Ferrer BioPharma, a world leader in the development of intranasal treatments. Utilizing cutting-edge nanoparticle technology, ClorNasal is specially formulated to provide fast and effective relief from allergy and rhinitis symptoms.
Anti-allergy intranasal spray
Quick relief of nasal symptoms
No drug interactions
Treats cough without sleepiness
No significant side-effects
Equipped with GentleMist Technology Nozzle "No burn, no pain"
How to use our Nasal Spray
Step 1
Remove the cap by pressing both sides marks and rotating counter clockwise
Step 2
Press down two times before first use to prime the product
Step 3
Don't tilt your head. Insert the nozzle into one nostril at a 45° angle, then press down firmly on the nozzle to release the spray and inhale deeply through the nostril.
80% of wound infections traced by DNA to bacteria in the patients' own nose
Approximately 60 million Americans suffer from allergies each year, making it the 6th leading cause of chronic illness in the country.
Intranasal corticosteroids are the most effective treatments for allergic rhinitis, providing relief for up to 80% of patients.
Research & Studies
Chlorpheniramine Maleate Nasal Spray In COVID-19 Patients: Case Series
This study suggests that utilizing chlorpheniramine maleate (CPM) nasal spray as an adjunct treatment to COVID-19 patients could potentially reduce their clinical course and hasten their time to negativization via RT-PCR via nasopharyngeal swab, as it has shown to be safe and effective against various strains of influenza A/B
Effective Nasal Disinfection as an Overlooked Strategy in Our Fight against COVID-19
The article discusses the potential of nasal disinfection and hygiene in controlling the spread of COVID-19, alongside measures such as handwashing, masks, and social distancing. Strongly recommending appropriate clinical trials
Evaluation of patient experience for a computationally-guided intranasal spray protocol to augment therapeutic penetration
This study emphasizes the need for reproducible and user-friendly intranasal drug delivery modalities that are effective in targeting the ineffective airway regions and promote compliance for the management of respiratory conditions including COVID-19
Intranasal therapy and COVID-19: A comprehensive literature review
This review explores the potential effectiveness of intranasal administration of agents with antiviral properties, as a novel strategy for decreasing viral activity in the nasal pathway and preventing transmission of SARS-CoV-2 and other viruses
Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence
This study explores the feasibility and efficacy of using an intranasally administered Chlorpheniramine Maleate spray as a treatment for COVID-19 through the nasal cavity, which is the portal of entry for the virus
In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2
The article highlights the similarities between COVID-19 and other respiratory viruses, and proposes that Chlorpheniramine maleate (CPM), a safe and effective antihistamine with broad antiviral activity, could potentially be used as antiviral nasal spray for the treatment of COVID-19
A Randomized Controlled Pilot Trial to Test the Efficacy of Intranasal Chlorpheniramine Maleate for the Treatment of Allergic Rhinitis
This study aimed to test the efficacy of intranasal chlorpheniramine maleate plus l (CPM) nasal for the treatment of allergic rhinitis in an outpatient setting, and the results suggest that nasal CPM use effectively improves AR symptomsThis study aimed to test the efficacy of intranasal chlorpheniramine maleate plus l (CPM) nasal for the treatment of allergic rhinitis in an outpatient setting, and the results suggest that nasal CPM use effectively improves AR symptoms
A Pathophysiological Perspective on COVID-19's Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation
The article proposes a theory that SARS-CoV-2 can trigger an immune reaction resembling hypersensitivity pneumonitis, especially in genetically vulnerable individuals and those with immune dysregulation, and suggests the need for early treatment to address the disease before immune dysregulation leads to uncontrolled pulmonary inflammation